No Data
No Data
BrightPath Biotherapeutics: 1Q financial results briefing for March 2025 [Japan standard] (non-consolidated).
McDonald's, Isetan Mitsukoshi, Rakuten G, ENEOS HD (9th) (1379-5076)
*The calendar above is tentative and subject to change due to company circumstances. ---------------------------------------August 9 (Friday) <1379> Hokuto <1381> Access <1384> Hokuriyo <1414> Showbond <1417> Miraito One <1429> Japan Aqua <142A> Gingerbread <1431> Livework <14
Will the search for double-digit stocks continue with elimination method vigilance?
The new emerging market this week may continue to be in a tough situation. In the US market over the weekend, the major stock indexes fell sharply due to concerns about economic slowdown, after the market expected the July employment statistics to be lower than expected. The growth market 250 index fell to the level of the COVID-19 shock in March 2020 as of last weekend, so it is likely to further decline this week. Although the yield on 10-year bonds in the US dropped significantly to below 3.8% since December last year, the Australian small/mid cap stocks, which are composed of small and medium-sized companies, may continue to decline.
Emerging markets outlook: be cautious of a one-step decline in the Growth Market 250 index, will continue to search for double-digit stocks by elimination method.
In the current market situation, there is strong selling pressure to avoid risks, and the emerging markets saw a significant decline this week. The rise and fall rates during this period showed that while the Nikkei average fell by -4.67%, the growth market index fell significantly further by -9.62%, and the growth market 250 index fell by -10.36%. Looking back as far as the former Mothers Index, this marked the lowest decline rate since the week of January 1, 2022, of -10.61%. Similar to the primary market, the strong selling pressure to avoid risk is due to factors such as the rapid appreciation of the yen after the meeting of the central banks of Japan, the US and China, and growing concern about a recession in the US economy.
Brightpath Bio, Solasia Pharma, etc.
<2164> Regional Newspaper Co., Ltd. Angel Torch stock ownership ratio 38.99% → 37.60% Report obligation occurrence date 07/22/2024 <4594> Bright Path Bio Co., Ltd. Macquarie Bank Limited stock ownership ratio 5.71% → 1.84% Report obligation occurrence date 07/22/2024 <4597> Solasia Pharma Co., Ltd. Macquarie Bank Limited stock ownership ratio
Macquarie decrases its stake in BrightPath Biotherapeutics(4594.JP) to 1.84%
On Jul 26, Macquarie submitted the Change Report to Ministry of Finance. The report shows that Macquarie decreased their holdings in $BrightPath Biotherapeutics(4594.JP)$, with their joint
No Data